Latest Ratios: P/E Ratio -21.6x · EV/EBITDA N/A · ROE -188.0%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $757M | $165M | $93M | $130M | $95M | — | — |
| Enterprise Value | $725M | $133M | $74M | $111M | $75M | — | — |
| P/E Ratio → | -21.61 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 33.80 | 8.94 | 9.53 | 10.63 | 6.68 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -188.0% | -188.0% | -173.4% | -168.5% | -1188.7% | — | — |
| ROA | -105.1% | -105.1% | -100.6% | -112.5% | -141.0% | -193.6% | — |
| ROIC | — | — | — | — | — | — | — |
| ROCE | -196.1% | -196.1% | -181.1% | -173.3% | -208.4% | -236.9% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.72 | -1.91 | -1.57 | -1.41 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — |
Net cash position: cash ($32M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.38 | 2.38 | 2.09 | 2.75 | 3.30 | 2.41 | — |
| Quick Ratio | 2.38 | 2.38 | 2.09 | 2.75 | 3.30 | 2.41 | — |
| Cash Ratio | 2.38 | 2.38 | 2.08 | 2.74 | 3.23 | 2.37 | — |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $22M | $17M | $16M | $13M | $13M | $13M |
Clinical Trial Funding Dependency
According to recent market data, NVCT trades at a price-to-book ratio of 32.21, which suggests that investors are assigning a significant premium to the company's intellectual property portfolio despite the absence of revenue and the inherent binary risks associated with its early-stage oncology pipeline.
The elevated P/B multiple reflects the market's valuation of the HSF1 and Src inhibition platforms rather than tangible assets. This valuation appears highly sensitive to clinical catalyst timing, and investors should monitor whether this premium can be sustained if clinical enrollment timelines face further delays.
Based on reported financial statements, NVCT's current ratio has fluctuated between 2.09 and 3.46 over the last ten quarters, indicating that while the firm maintains a short-term liquidity cushion, the consistent depletion of cash reserves necessitates a disciplined approach to capital management to avoid future dilution.
The current ratio provides a misleading sense of security, as the lack of revenue means that liquidity is entirely dependent on the remaining cash balance. The downward trend in total assets suggests that the company is consuming its capital base to fund R&D, which warrants further investigation into the timing of potential future financing rounds.
As reported in peer comparison data, NVCT's P/B ratio of 32.21 sits at the high end of the cohort, suggesting that the market may be pricing in a higher probability of success for its specific transcription factor targets compared to peers like Kymera Therapeutics.
The valuation gap between NVCT and its peers appears structural, driven by the unique nature of the HSF1 pathway. However, investors should be cautious, as this premium may be vulnerable to re-rating if clinical data fails to demonstrate the anticipated safety and efficacy advantages over existing inhibitors.
The most commonly misapplied metric for NVCT is the P/E ratio, which, at -20.60, obscures the company's true operational health by focusing on GAAP net losses that include non-cash items like stock-based compensation rather than the actual cash burn required to sustain clinical development.
Analysts should prioritize cash burn and clinical milestone progress over earnings-based metrics, as the latter are irrelevant for a pre-revenue biotechnology firm. Relying on P/E ratios in this context may lead to incorrect conclusions regarding the company's financial viability and its long-term capital requirements.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NVCT stock.
Nuvectis Pharma, Inc.'s current P/E ratio is -21.6x. This places it at the 50th percentile of its historical range.
Nuvectis Pharma, Inc.'s return on equity (ROE) is -188.0%. The historical average is -176.6%.
Based on historical data, Nuvectis Pharma, Inc. is trading at a P/E of -21.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.